Tisagenlecleucel, a 4-1BB costimulated CD19 CAR-T product approved for R/R pediatric ALL and adult NHL, was studied in pediatric B-NHL, and early results were presented at the 2022 European Hematology Association annual meeting. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.